Leveraging High-Throughput Experimentation to Drive Pharmaceutical Route Invention: A Four-Step Commercial Synthesis of Branebrutinib (BMS-986195)
01 natural sciences
0104 chemical sciences
DOI:
10.1021/acs.oprd.1c00443
Publication Date:
2022-02-15T13:00:29Z
AUTHORS (12)
ABSTRACT
The invention of a commercial route to the Bruton's tyrosine kinase inhibitor branebrutinib (BMS-986195) in four total chemical steps is described. execution high-throughput experimentation (HTE) coupled with first-principles approach across proposed synthetic enabled identification novel indolization reaction that rapidly generated high complexity, as centerpiece synthesis. A parallel HTE strategy during design efficient and rapid evaluation multiple options within short timeframe complete rigorous process development while mitigating risks associated implementing new chemistry featuring an aggressive disconnection strategy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (19)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....